HMOX1 and acute myeloid leukemia: These findings align with previous observations in AML, furthermore, the co-expression of Nrf2 and HO-1 in ESCC patients has been linked to even worse prognoses, suggesting a synergistic effect in promoting tumor progression and immune evasion.